InvestSMART

Lumos Diagnostics Holdings Limited (ASX:LDX)

ALERT: Price-sensitive ASX Announcement for LDX
Current share price for LDX : $0.105 -0.16 (-60.38%)+
Announcement
Release
27 Mar 2026 10:08AM
Price at Release
$0.265
Full Release
download
Summary
Lumos Diagnostics Holdings Limited has successfully completed an institutional placement raising A$20 million to support the commercialization of its FebriDx test in the United States following its CLIA waiver by the FDA. The company has also launched a Share Purchase Plan (SPP) aiming to raise an additional A$2 million for eligible shareholders. The proceeds from these initiatives will be utilized to expand the manufacturing, sales, and marketing capacities in the US market, targeting a significant market expansion for FebriDx. The placement involved issuing up to 88.9 million new shares at a price of A$0.225 each, with MST, Barrenjoey, and Foster Stockbroking acting as joint lead managers and bookrunners. An upcoming webinar will be organized to further inform shareholders about the SPP details.
Key Points
  • Lumos completes A$20m institutional placement
  • Launches Share Purchase Plan (SPP) to raise A$2m
  • Proceeds to support US commercialization of FebriDx
  • Funds to expand manufacturing and marketing in the US
  • CLIA waiver received for FebriDx by US FDA
  • Placement involved issue of 88.9m new shares
  • Placement price at A$0.225 per share
  • SPP shares offered at the same price as Placement
  • Bookrunners were MST, Barrenjoey, and Foster Stockbroking
  • Webinar to be conducted for shareholders about SPP
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.